Anti-COVID-19 measurements for hidradenitis suppurativa patients

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

  • Evangelos J. Giamarellos-Bourboulis
  • Vincenzo Bettoli
  • Jemec, Gregor
  • Veronique del Marmol
  • Angelo V. Marzano
  • Errol P. Prens
  • Thrasyvoulos Tzellos
  • Christos C. Zouboulis

The reported incidence of COVID-19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID-19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID-19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti-COVID-19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS-CoV2 and patients affected by metabolic syndrome constitute a high-risk group for COVID-19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non-living virus anti-SARS-CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.

OriginalsprogEngelsk
TidsskriftExperimental Dermatology
Vol/bind30
Udgave nummerS1
Sider (fra-til)18-22
Antal sider5
ISSN0906-6705
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
The Department of Dermatology, Zealand University Hospital, Faculty of Health Science, University of Copenhagen, Denmark; the Department of Dermatology, H?pital Erasme, Universite Libre de Bruxelles, Bruxelles, Belgium; the Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands; and the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany are healthcare providers of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin ? ALLOCATE Skin group).

Funding Information:
EJG‐B, VB, GBEJ, VdM, AVM, EPP, TT, CCZ declare that none of the mentioned conflicts of interest had any influence to this manuscript. EJG‐B has received honoraria from Abbott, Angelini, bioMérieux, InflaRx, MSD and XBiotech; independent educational grants from AbbVie, Abbott, Astellas, AxisShield, bioMérieux, InflaRx, Thermo Fisher Brahms and XBiotech; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie‐Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens) and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). GBEJ has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Kymera Therapeutics, LEO, Novartis and UCB for participation on advisory boards, and grants from Abbvie, Astra‐Zeneca, Inflarx, Janssen‐Cilag, LEO, Novartis, Regeneron and Sanofi for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer‐Ingelheim, Galderma and Novartis. He has also received unrestricted departmental grants from LEO and Novartis. VdM has received honoraria for advisory board participation from BMS, Leo Pharma, Sanofi. EPP received honoraria from AbbVie, Amgen, Celgene, Galderma, Janssen‐Cilag, Novartis and Pfizer for participation as a speaker and serving on advisory boards and investigator‐initiated grants (paid to the Erasmus MC) from AbbVie, AstraZeneca, Janssen‐Cilag and Pfizer. TT reports fees from AbbVie, UCB and Sanofi (consultancy, speaker honorarium). CCZ has received thematically relevant honoraria from Incyte, Inflarx, Janssen‐Cilag, Novartis, Regeneron and UCB as advisor. His departments have received grants from AbbVie, AOTI, Astra Zeneca, Galderma, Inflarx, Naos‐Bioderma, Novartis, PPM and UCB for his participation as clinical investigator. AVM declares no conflict of interest.

Publisher Copyright:
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Links

ID: 272174523